Novel drugs for oral anticoagulation pharmacotherapy

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 4, 2012, Pages 473-488

  Capodanno, Davide ^a,b   Giacchi, Giuseppe ^a   Tamburino, Corrado ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b ETNA Foundation   (Italy)

Author keywords

apixaban; dabigatran; edoxaban; novel oral anticoagulants; rivaroxaban

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; AZD 0837; BETRIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ENOXAPARIN; HEPARIN; LETAXABAN; LIXIANA; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EMBOLISM; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84859458005     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.18     Document Type: Review

References (50)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 160S-198S (2008). (Pubitemid 351892967)
2. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke Prevention With the Oral Direct Thrombin Inhibitor Ximelagatran Compared With Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised controlled trial. Lancet 362, 1691-1698 (2003). (Pubitemid 37468318)
3. Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293, 690-698 (2005).
4. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann. Intern. Med. 131, 927-934 (1999). (Pubitemid 30005032)
5. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47, 285-295 (2008). (Pubitemid 351508116)
6. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579 (2011).
7. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, noninferiority trial. Lancet 370, 949-956 (2007). (Pubitemid 47393577)
8. Eriksson BI, Dahl OE, Huo MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, noninferiority trial. Thromb. Haemost. 105, 721-729 (2011).
9. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J. Thromb. Haemost. 5, 2178-2185 (2007). (Pubitemid 47617868)
10. Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate versus North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24, 1-9 (2009).
11. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb. Haemost. 101, 77-85 (2009).
12. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342-2352 (2009).
13. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
14. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363, 1875-1876 (2010).
15. Wann LS, Curtis AB, Ellenbogen KA et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). J. Am. Coll. Cardiol. 57, 1330-1337 (2001).
16. Beasley BN, Unger EF, Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 364, 1788-1790 (2011).
17. Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, Phase II trial. Eur. Heart J. 32, 2781-2789 (2011).
18. Johansson S, Cullberg M, Eriksson UG et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int. J. Clin. Pharmacol. Ther. 49, 258-267 (2011).
19. Lip GYH, Rasmussen LH, Olsson SB et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: A randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs vitamin K antagonists. Eur. Heart J. 30, 2897-2907 (2009).
20. Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel anti-Thrombotic agent BAY 59-7939 - An oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3, 514-521 (2005). (Pubitemid 41632877)
21. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: A new oral Factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol. 30, 376-381 (2010).
22. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008). (Pubitemid 351930851)
23. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-Term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet 372, 31-39 (2008).
24. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008). (Pubitemid 351930852)
25. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet 373, 1673-1680 (2009).
26. Turpie AG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 105, 444-453 (2011).
27. Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombolysis 31, 407-416 (2011).
28. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-2510 (2010).
29. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883-891 (2011).
30. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, Phase II trial. Lancet 374, 29-38 (2009).
31. Mega JL, Braunwald E, Wiviott SD et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19 (2012).
32. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37, 74-81 (2009).
33. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594-604 (2009).
34. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet 375, 807-815 (2010).
35. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363, 2487-2498 (2010).
36. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-ana-lysis of randomised trials. Thromb. Haemost. 105, 245-253 (2011).
37. Leizorovicz A, Kakkar AK, Haas SK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365, 2167-2177 (2011).
38. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806-817 (2011).
39. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
40. Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119, 2877-2885 (2009).
41. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365, 699-708 (2011).
42. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J. Clin. Pharmacol. 50, 743-753 (2010).
43. Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160, 635-641 (2010).
44. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur. Heart J. 29, 155-165 (2008).
45. Eriksson BI, Turpie AG, Lassen MR et al. Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J. Thromb. Haemost. 8, 714-721 (2010).
46. Steg G, Mehta SR, Jukema JM. RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur. Heart J. 32, 2541-2554 (2011).
47. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A Phase II study of the oral Factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J. Thromb. Haemost. 5, 746-753 (2007). (Pubitemid 46563573)
48. Weitz JI, Cao C, Eriksson BI et al. A dose-finding study with TAK-442, an oral Factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb. Haemost. 104, 1150-1157 (2010).
49. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 376, 975-983 (2010).
50. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (2007). (Pubitemid 350154345)